Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.

OBJECTIVE Antiapoptotic Bcl-2 is overexpressed in most cases of chronic lymphocytic leukemia (CLL). The inhibition of the antiapoptotic Bcl-2 proteins is an attractive strategy for either restoring normal apoptotic process in cancer cells or making these cells more susceptible to conventional chemotherapy. We studied the effect of Bcl-2 inhibitors on the viability of cells from CLL and other mature B-cell neoplasms. MATERIALS AND METHODS We studied the cytotoxic effects of four nonpeptidic cell-permeable Bcl-2 inhibitors (HA14-1, antimycin A, GX15-003, and GX15-070) on B cells from patients with CLL, mantle cell lymphoma (MCL), and splenic marginal zone lymphoma (SMZL). Moreover, we analyzed the effect of these inhibitors in combination with fludarabine or chlorambucil. RESULTS HA14-1 induced apoptosis with an EC50 lower than 50 microM in 26 of the 36 CLL samples analyzed. The mean EC50 for these sensitive patients was 23 +/- 2 microM. Antimycin A induced apoptosis in 13 of the 18 CLL samples analyzed. Both HA14-1 and antimycin A induced cytochrome c release from mitochondria and caspase-3 activation. Moreover, HA14-1 induced apoptosis in peripheral cells from MCL and SMZL. HA14-1 also induced apoptosis in CLL samples with alterations in p53 or ATM. Finally, GX compounds induced apoptosis in B cells from 9 of the 11 CLL samples tested. The combination of either HA14-1, antimycin A, or GX compounds with fludarabine or chlorambucil had additive cytotoxic effects on CLL cells. CONCLUSION Bcl-2 inhibitors induce apoptosis in CLL cells ex vivo and could be used in CLL as monotherapy or given in combination with current chemotherapy.

[1]  J. Tan,et al.  HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death , 2003, Leukemia.

[2]  G. Pons,et al.  The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells , 2007, Haematologica.

[3]  J. Slupsky,et al.  B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. , 2007, Blood.

[4]  F. Sinicrope,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells , 2004, Clinical Cancer Research.

[5]  J. Schouten,et al.  Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. , 2003, Nucleic acids research.

[6]  E. Remmerswaal,et al.  CD40 stimulation of B‐cell chronic lymphocytic leukaemia cells enhances the anti‐apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T‐lymphocyte attack , 2004, British journal of haematology.

[7]  T. McDonnell,et al.  Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. , 1996, Journal of immunology.

[8]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[9]  Luca Laurenti,et al.  The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. , 2008, Blood.

[10]  G Leone,et al.  The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease , 2007, Leukemia.

[11]  Ruey-min Lee,et al.  The apoptotic effect of HA14-1, a Bcl-2-interacting small molecular compound, requires Bax translocation and is enhanced by PK11195. , 2002, Molecular cancer therapeutics.

[12]  J. Marshall,et al.  A phase I study of the pan-Bcl2 family inhibitor GX15-070, administered as a 3-hour weekly infusion in patients with refractory solid tumors or lymphomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[14]  J. Fisher,et al.  Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo. , 2005, Neoplasia.

[15]  Ken Garber,et al.  New apoptosis drugs face critical test , 2005, Nature Biotechnology.

[16]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[17]  T. Hunter,et al.  Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition , 2007, Oncogene.

[18]  Dylan T. Jones,et al.  Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis. , 2003, Blood.

[19]  J. Gil,et al.  Protein Kinases in the Regulation of Apoptosis in B-cell Chronic Lymphocytic Leukemia , 2003, Leukemia & lymphoma.

[20]  N. Chiorazzi,et al.  mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .

[21]  J. Plate.  PI3-Kinase Regulates Survival of Chronic Lymphocytic Leukemia B-Cells by Preventing Caspase 8 Activation , 2004, Leukemia & lymphoma.

[22]  K. Rai,et al.  Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Colomer,et al.  Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia , 2003, Leukemia.

[24]  E. Montserrat,et al.  Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. , 1998, Blood.

[25]  M. Konopleva,et al.  Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. , 2002, Blood.

[26]  F. Mancini,et al.  p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. , 1998, Blood.

[27]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[28]  M. Fey,et al.  Disparate expression of the PTEN gene: a novel finding in B‐cell chronic lymphocytic leukaemia (B‐CLL) , 2003, British journal of haematology.

[29]  B. Cheson,et al.  Initial results from ongoing phase I trials of a novel pan bcl-2 family small molecule inhibitor , 2005 .

[30]  G. Delespesse,et al.  Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression , 1992, The Journal of experimental medicine.

[31]  P. Lydyard,et al.  B Cell Response to Surface IgM Cross-Linking Identifies Different Prognostic Groups of B-Chronic Lymphocytic Leukemia Patients 1 , 2005, The Journal of Immunology.

[32]  M. T. de la Fuente,et al.  Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells. , 2004, Biochemical and biophysical research communications.

[33]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[34]  D. Green,et al.  Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. , 2006, Molecular cell.

[35]  Yun Dai,et al.  The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. , 2004, Molecular cancer therapeutics.

[36]  T. Mak,et al.  FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal , 2006, The Journal of experimental medicine.

[37]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J J Hill,et al.  Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand, antimycin A. , 2001, Biochemistry.

[39]  J. An,et al.  Critical Upstream Signals of Cytochrome c Release Induced by a Novel Bcl-2 Inhibitor* , 2004, Journal of Biological Chemistry.

[40]  K. Do,et al.  Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL) , 2002, Leukemia.

[41]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Kessel,et al.  Susceptibility of myelomonocytic leukemia U937 cells to the induction of apoptosis by the non-peptidic Bcl-2 ligand HA14-1 is cell cycle phase-dependent. , 2005, Cancer letters.

[43]  T. Kipps,et al.  Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation , 2005, Leukemia.

[44]  E. Cesarman,et al.  Survival of leukemic B cells promoted by engagement of the antigen receptor. , 2001, Blood.

[45]  S. Grant,et al.  The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells , 2003, Leukemia.

[46]  N Tsukada,et al.  Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. , 2000, Blood.

[47]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[48]  John Calvin Reed,et al.  Apoptosis-based therapies for hematologic malignancies. , 2005, Blood.

[49]  Gabriel Pons,et al.  MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.

[50]  M. Keating.  Immunosuppression with purine analogues--the flip side of the gold coin. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  Michael Keane,et al.  Characterization of a Protein Kinase B Inhibitor In Vitro and in Insulin-Treated Liver Cells , 2007, Diabetes.

[52]  D. Colomer,et al.  Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. , 2003, Blood.

[53]  Kam Y. J. Zhang,et al.  Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 , 2001, Nature Cell Biology.

[54]  D. Colomer,et al.  Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. , 2002, Blood.

[55]  T. Zheng.  Death by design: the big debut of small molecules , 2001, Nature Cell Biology.

[56]  G. Pons,et al.  Regulation of Akt/PKB by phosphatidylinositol 3‐kinase‐dependent and ‐independent pathways in B‐cell chronic lymphocytic leukemia cells: role of protein kinase Cβ , 2006, Journal of leukocyte biology.

[57]  D. Jong,et al.  Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection , 2007, Cell Death and Differentiation.

[58]  A. Morales,et al.  High expression of Bfl‐1 contributes to the apoptosis resistant phenotype in B‐cell chronic lymphocytic leukemia , 2005, International journal of cancer.

[59]  F. Cotter,et al.  Antisense‐mediated suppression of Bcl‐2 highlights its pivotal role in failed apoptosis in B‐cell chronic lymphocytic leukaemia , 1999, British journal of haematology.

[60]  C. Croce,et al.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. , 1998, Blood.

[61]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[62]  O. Bairey,et al.  Expression of bcl‐2 and bax in cellsisolated from B‐chronic lymphocytic leukemia patients at differentstages of the disease , 2000, European journal of haematology.

[63]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[64]  John Calvin Reed,et al.  bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia , 1993 .

[65]  C. Peschel,et al.  Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. , 2002, Blood.

[66]  S. Korsmeyer,et al.  Antiapoptotic BCL-2 is required for maintenance of a model leukemia. , 2004, Cancer cell.

[67]  B. Cheson,et al.  A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL). , 2005 .

[68]  T. Kipps,et al.  Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia , 1990, The Journal of experimental medicine.

[69]  D. Oscier,et al.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.

[70]  E. Montserrat,et al.  In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. , 1999, Blood.

[71]  M. King,et al.  Antimycin A-induced apoptosis of HL-60 cells. , 2002, Cytometry.

[72]  G. Cohen,et al.  Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1 , 2003, Leukemia.

[73]  John Calvin Reed,et al.  Bryostatin and CD40‐ligand enhance apoptosis resistance and induce expression of cell survival genes in B‐cell chronic lymphocytic leukaemia , 1999, British journal of haematology.

[74]  Yan Shi,et al.  Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo , 2005, Molecular Cancer Therapeutics.

[75]  S. Gibson,et al.  Lysophosphatidic Acid (LPA) Protects Primary Chronic Lymphocytic Leukemia Cells from Apoptosis through LPA Receptor Activation of the Anti-apoptotic Protein AKT/PKB* , 2005, Journal of Biological Chemistry.

[76]  A. Newland,et al.  Bcl-2 Inhibitors Sensitize Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Uncoupling of Mitochondrial Respiration in Human Leukemic CEM Cells , 2004, Cancer Research.

[77]  S. Shangary,et al.  Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family , 2003, Leukemia.

[78]  J. Pelkonen,et al.  HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. , 2006, Leukemia research.

[79]  L. Moretti,et al.  bcl-2 gene expression in hematopoietic cell differentiation , 1992 .

[80]  T. McDonnell,et al.  Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. , 1996, Leukemia.